30 closest matches · ranked by relevance
PTEN Gene Mutation · PTEN Hamartoma Tumor Syndrome
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Dropout — 3; 2; 5; 2 Participants
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
TSC1 · TSC2 · Tuberous Sclerosis Complex
Primary: Objective Response Rate — 2 Participants
Breast Cancer · Ovarian Cancer
Primary: Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population. — 22 Participants
Advanced Breast Carcinoma · Advanced Malignant Solid Neoplasm · Advanced Prostate Carcinoma
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 2; 0; 0; 0 Participants
PIK3CA-Related Overgrowth Spectrum (PROS) · Growth Disorder · Genetics
Primary: Percent Change in Unaffected and Affected Fibrofatty Tissue Measured by DXA — 7.9; 4.8; 0.71; 6.5 mean percentage change in tissue volume
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Frontotemporal Lobar Degeneration (FTLD) · Frontotemporal Dementia (FTD) · Tauopathies
Primary: SUVR of 18F-AV-1451 — 1.07; 1.26; 1.03; 1.34 standardized uptake value ratio (SUVR)
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Anti-p53 TCR-Gene
Primary: Clinical Tumor Regression — 1 Participants
Breast Cancer
Primary: Clinical Benefit Rate — 0.12 proportion of participants
Advanced Malignant Solid Neoplasm
Primary: Number of Participants With an Objective Response — 0; 0; 0; 0 Participants
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
Metastatic Breast Cancer
Primary: Progression-free Survival (PFS) — 4.4 Months
Thymoma
Primary: Percent of Patients With Objective Response — 7.1 percentage of participants
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Non Small Cell Lung Cancer
Primary: Overall Response Rate — 0 Participants
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Non-Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 5 Percentage of participants
Ovarian Sarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma
Primary: Efficacy (as Measured by Objective Response Rate) of Akt Inhibitor MK2206 in Patients With Recurrent High-grade Platinum-resistant Serous Ovarian, Fallopian Tube, or…
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic
Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants